New combo vaccine and immunotherapy tackles Hard-to-Treat breast cancer

NCT ID NCT03328026

Completed Disease control Sponsor: BriaCell Therapeutics Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a personalized cancer vaccine (SV-BR-1-GM) combined with an immunotherapy drug (retifanlimab) in 36 people with advanced breast cancer that had stopped responding to standard treatments. The vaccine is made from the patient's own tumor cells and aims to train the immune system to attack the cancer. The study checked for safety and side effects, and also looked at whether tumors shrank. Results are not yet available, but the approach could offer a new option for patients with few choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SV-BR-1-GM (a personalized breast cancer cell vaccine), low-dose cyclophosphamide, interferon, and retifanlimab (an immunotherapy drug)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with advanced breast cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply to everyone. The treatment may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER, METASTATIC BREAST NEOPLASM METASTATIC BREAST CANCER

Contacts and locations

Locations

Cancer Center of Kansas (CCK)

Wichita, Kansas, 67214, United States
Carle Cancer Institute

Urbana, Illinois, 61801, United States
Hematology-Oncology Associates of Fredericksburg, Inc

Fredericksburg, Virginia, 22408, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Manhattan Hematology Oncology Associates (MHOA)

Manhattan, New York, 10016, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States
Overlook Medical Center Oncology Research, Atlantic Health System

Summit, New Jersey, 07901, United States
St Vincent-Frontier Cancer Center

Billings, Montana, 59102, United States
St. Joseph Heritage Healthcare

Santa Rosa, California, 95403, United States
The Center for Cancer and Blood Disorders a division of American Oncology Partners MD

Bethesda, Maryland, 20817, United States
Tranquil Clinical Research

Webster, Texas, 77598, United States
University of Miami/Sylvester at Plantation

Plantation, Florida, 33324, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.